IDEAYA Biosciences to be Acquired for $1.1 Billion

TL;DR

IDEAYA acquired for $1.1B cash by HealthCare Royalty Partners IV, closing H1 2025.

AI Summary

IDEAYA Biosciences, Inc. announced on October 25, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of HealthCare Royalty Partners IV, L.P. for $1.1 billion in cash. The transaction is expected to close in the first half of 2025, subject to customary closing conditions.

Why It Matters

This acquisition represents a significant financial event for IDEAYA Biosciences, providing substantial cash value to shareholders and potentially impacting the future development of its drug pipeline.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.

Key Numbers

• $1.1B — Acquisition Price (Total cash consideration for IDEAYA Biosciences)

Key Players & Entities

• IDEAYA Biosciences, Inc. (company) — Company being acquired
• HealthCare Royalty Partners IV, L.P. (company) — Acquiring entity
• $1.1 billion (dollar_amount) — Acquisition price
• October 25, 2024 (date) — Date of announcement and agreement
• first half of 2025 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq

Filing Documents

• d898951d8k.htm (8-K) — 33KB
• 0001193125-24-243413.txt ( ) — 156KB
• idya-20241025.xsd (EX-101.SCH) — 3KB
• idya-20241025_lab.xml (EX-101.LAB) — 18KB
• idya-20241025_pre.xml (EX-101.PRE) — 11KB
• d898951d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to (i) expectations regarding the clinical activity profile and potential advantages of the Company's clinical programs, (ii) the timing of enrollment for the IDE397 Phase 2 monotherapy expansion in MTAP-deletion lung and bladder cancer and (iii) the timing of initiation of the IDE397 and Trodelvy Phase 1/2 combination expansion in MTAP-deletion urothelial cancer. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: October 25, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR